Please assess the completion status of the following clinical trial:

Trial Title: Repeat Emergency Department Visits Among Patients With Asthma and COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treated in the ED at the Erie County Medical Center (ECMC) for acute symptoms of asthma or COPD during the study period~* Patient age ≥ 18 years~* Resident of the City of Buffalo or Erie County~* Discharged to home~* Patient expresses willingness to return to ECMC or own primary care provider for follow-up visits~* Able to provide informed consent~* Able to comprehend English language~Exclusion Criteria:~* Received oral or inhaled corticosteroids in the week before ED presentation~* Presented to the ED primarily for prescription refills~* Complicated comorbid conditions (e.g. renal disease, cardiovascular disease, CHF, HIV)~* Admitted to ECMC or discharged to another facility~* Previously enrolled during a prior visit to the ED during the study period~* For female patients--pregnant or pregnancy status indeterminate~* Antibiotics are prescribed to treat current asthma/COPD exacerbation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard of Care: 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 4 days (1st dose will have been given in the ED)~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.
- Treatment (Type: EXPERIMENTAL): Treatment: 30 day QVAR® (beclamethasone dipropionate) inhaler (80 mcg, 1 puff twice daily) plus 30 day albuterol inhaler plus non-tapering course of oral prednisone (50 mg/d) for 5 days~Spacers will be dispensed with all multiple dose inhalers (MDI) to promote proper use and administration of inhaled medications.

Based on this trial design, predict the completion outcome and termination type (if applicable).